Retreatment with Pegylated Interferon Alpha-2a and Ribavirin in Patients with Chronic Hepatitis C Who Have Relapsed or Not Responded to a First Course of Pegylated Interferon-Based Therapy
BACKGROUND: Pegylated interferon (pegIFN) and ribavirin combination therapy remains the first-line treatment for chronic hepatitis C virus (HCV) infection. In contrast to the wealth of studies in treatment-naive patients, the effectiveness of retreatment in patients who have previously failed pegIFN...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2009-01-01
|
| Series: | Canadian Journal of Gastroenterology |
| Online Access: | http://dx.doi.org/10.1155/2009/470532 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832549361780785152 |
|---|---|
| author | Eric M Yoshida Morris Sherman Vincent G Bain Curtis L Cooper Marc Deschênes Paul J Marotta Samuel S Lee Mel Krajden Helga Witt-Sullivan Robert J Bailey Christopher Usaty Kevork Peltekian the Canadian Pegasys Study Group |
| author_facet | Eric M Yoshida Morris Sherman Vincent G Bain Curtis L Cooper Marc Deschênes Paul J Marotta Samuel S Lee Mel Krajden Helga Witt-Sullivan Robert J Bailey Christopher Usaty Kevork Peltekian the Canadian Pegasys Study Group |
| author_sort | Eric M Yoshida |
| collection | DOAJ |
| description | BACKGROUND: Pegylated interferon (pegIFN) and ribavirin combination therapy remains the first-line treatment for chronic hepatitis C virus (HCV) infection. In contrast to the wealth of studies in treatment-naive patients, the effectiveness of retreatment in patients who have previously failed pegIFN-based therapy is largely unreported. |
| format | Article |
| id | doaj-art-2555567b69fc42b6807edfc1730ef787 |
| institution | Kabale University |
| issn | 0835-7900 |
| language | English |
| publishDate | 2009-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology |
| spelling | doaj-art-2555567b69fc42b6807edfc1730ef7872025-02-03T06:11:29ZengWileyCanadian Journal of Gastroenterology0835-79002009-01-0123318018410.1155/2009/470532Retreatment with Pegylated Interferon Alpha-2a and Ribavirin in Patients with Chronic Hepatitis C Who Have Relapsed or Not Responded to a First Course of Pegylated Interferon-Based TherapyEric M Yoshida0Morris Sherman1Vincent G Bain2Curtis L Cooper3Marc Deschênes4Paul J Marotta5Samuel S Lee6Mel Krajden7Helga Witt-Sullivan8Robert J Bailey9Christopher Usaty10Kevork Peltekian11the Canadian Pegasys Study GroupDivision of Gastroenterology, University of British Columbia, Vancouver, British Columbia, CanadaUniversity Health Network, Toronto, Ontario, CanadaUniversity of Alberta, Edmonton, Alberta, CanadaUniversity of Ottawa, Ottawa, Ontario, CanadaRoyal Victoria Hospital, Montreal, Quebec, CanadaUniversity of Western Ontario, London, Ontario, CanadaUniversity of Calgary, Calgary, Alberta, CanadaBC Centre for Disease Control, Vancouver, British Columbia, CanadaMcMaster University, Hamilton, Ontario, CanadaRoyal Alexandra Hospital, Edmonton, Alberta, CanadaRoche, Mississauga, Ontario, CanadaDalhousie University, Halifax, Nova Scotia, CanadaBACKGROUND: Pegylated interferon (pegIFN) and ribavirin combination therapy remains the first-line treatment for chronic hepatitis C virus (HCV) infection. In contrast to the wealth of studies in treatment-naive patients, the effectiveness of retreatment in patients who have previously failed pegIFN-based therapy is largely unreported.http://dx.doi.org/10.1155/2009/470532 |
| spellingShingle | Eric M Yoshida Morris Sherman Vincent G Bain Curtis L Cooper Marc Deschênes Paul J Marotta Samuel S Lee Mel Krajden Helga Witt-Sullivan Robert J Bailey Christopher Usaty Kevork Peltekian the Canadian Pegasys Study Group Retreatment with Pegylated Interferon Alpha-2a and Ribavirin in Patients with Chronic Hepatitis C Who Have Relapsed or Not Responded to a First Course of Pegylated Interferon-Based Therapy Canadian Journal of Gastroenterology |
| title | Retreatment with Pegylated Interferon Alpha-2a and Ribavirin in Patients with Chronic Hepatitis C Who Have Relapsed or Not Responded to a First Course of Pegylated Interferon-Based Therapy |
| title_full | Retreatment with Pegylated Interferon Alpha-2a and Ribavirin in Patients with Chronic Hepatitis C Who Have Relapsed or Not Responded to a First Course of Pegylated Interferon-Based Therapy |
| title_fullStr | Retreatment with Pegylated Interferon Alpha-2a and Ribavirin in Patients with Chronic Hepatitis C Who Have Relapsed or Not Responded to a First Course of Pegylated Interferon-Based Therapy |
| title_full_unstemmed | Retreatment with Pegylated Interferon Alpha-2a and Ribavirin in Patients with Chronic Hepatitis C Who Have Relapsed or Not Responded to a First Course of Pegylated Interferon-Based Therapy |
| title_short | Retreatment with Pegylated Interferon Alpha-2a and Ribavirin in Patients with Chronic Hepatitis C Who Have Relapsed or Not Responded to a First Course of Pegylated Interferon-Based Therapy |
| title_sort | retreatment with pegylated interferon alpha 2a and ribavirin in patients with chronic hepatitis c who have relapsed or not responded to a first course of pegylated interferon based therapy |
| url | http://dx.doi.org/10.1155/2009/470532 |
| work_keys_str_mv | AT ericmyoshida retreatmentwithpegylatedinterferonalpha2aandribavirininpatientswithchronichepatitiscwhohaverelapsedornotrespondedtoafirstcourseofpegylatedinterferonbasedtherapy AT morrissherman retreatmentwithpegylatedinterferonalpha2aandribavirininpatientswithchronichepatitiscwhohaverelapsedornotrespondedtoafirstcourseofpegylatedinterferonbasedtherapy AT vincentgbain retreatmentwithpegylatedinterferonalpha2aandribavirininpatientswithchronichepatitiscwhohaverelapsedornotrespondedtoafirstcourseofpegylatedinterferonbasedtherapy AT curtislcooper retreatmentwithpegylatedinterferonalpha2aandribavirininpatientswithchronichepatitiscwhohaverelapsedornotrespondedtoafirstcourseofpegylatedinterferonbasedtherapy AT marcdeschenes retreatmentwithpegylatedinterferonalpha2aandribavirininpatientswithchronichepatitiscwhohaverelapsedornotrespondedtoafirstcourseofpegylatedinterferonbasedtherapy AT pauljmarotta retreatmentwithpegylatedinterferonalpha2aandribavirininpatientswithchronichepatitiscwhohaverelapsedornotrespondedtoafirstcourseofpegylatedinterferonbasedtherapy AT samuelslee retreatmentwithpegylatedinterferonalpha2aandribavirininpatientswithchronichepatitiscwhohaverelapsedornotrespondedtoafirstcourseofpegylatedinterferonbasedtherapy AT melkrajden retreatmentwithpegylatedinterferonalpha2aandribavirininpatientswithchronichepatitiscwhohaverelapsedornotrespondedtoafirstcourseofpegylatedinterferonbasedtherapy AT helgawittsullivan retreatmentwithpegylatedinterferonalpha2aandribavirininpatientswithchronichepatitiscwhohaverelapsedornotrespondedtoafirstcourseofpegylatedinterferonbasedtherapy AT robertjbailey retreatmentwithpegylatedinterferonalpha2aandribavirininpatientswithchronichepatitiscwhohaverelapsedornotrespondedtoafirstcourseofpegylatedinterferonbasedtherapy AT christopherusaty retreatmentwithpegylatedinterferonalpha2aandribavirininpatientswithchronichepatitiscwhohaverelapsedornotrespondedtoafirstcourseofpegylatedinterferonbasedtherapy AT kevorkpeltekian retreatmentwithpegylatedinterferonalpha2aandribavirininpatientswithchronichepatitiscwhohaverelapsedornotrespondedtoafirstcourseofpegylatedinterferonbasedtherapy AT thecanadianpegasysstudygroup retreatmentwithpegylatedinterferonalpha2aandribavirininpatientswithchronichepatitiscwhohaverelapsedornotrespondedtoafirstcourseofpegylatedinterferonbasedtherapy |